The Therapeutic Effect of Thalidomide in Syringomyelia
Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia.

Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.
- EligibilityCriteria: Inclusion Criteria:  Contraindication to duraplasty and shunting treatment due to history or high risk of severe adverse effects, or non-effective response to duraplasty and shunting treatment in 12 months prior to study entry. Estimated life expectancy must be greater than 12 months. Routine laboratory studies: bilirubin </=1.0 * upper limits of normal (ULN); aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT)< 1.0 * ULN; creatinine <1.0 * ULN; white-cell count >/= 4,000 per cubic millimeter; neutrophils count >/=1500 per cubic millimeter platelets >/= 100,000 per cubic millimeter; Hb >/=110 gram per millilitres; PT, APTT, INR in a normal range. Ability to understand and willingness to sign a written informed consent document, or constant caregivers who well understand and willingness to sign a written informed consent document. Must be able to swallow tablets  Exclusion Criteria:  Evidence of tumor metastasis, recurrence, or invasion; History of psychiatric diseases ; History of seizures; History of arteriosclerotic cardiovascular diseases (ASCVD), e.g. stroke, myocardial infaction, unstable angina, within 6 months; New York Heart Association Grade II or greater congestive heart failure; Serious and inadequately controlled cardiac arrhythmia; Significant vascular disease, e.g. moderate or severe carotid stenosis, aortic aneurysm, history of aortic dissection; Severe infection; History of allergy to relevant drugs; Pregnancy, lactation, or fertility program in the following 12 months; History or current diagnosis of peripheral nerve disease; Abnormal in liver and renal function; Active tuberculosis; Transplanted organs; Human immunodeficiency virus; Participation in other experimental studies. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult